News

Number of news items returned: 61 to 80 records of 422

Opmantek named 55th Australian Export Awards category winner

15 December 2017

(7900 views)

  Opmantek named  55th Australian Export Awards category winner     On the back of winning the 4th consecutive Queensland Premier's Export Award, Opmantek ...

BlueMount Capital Secures Major Debt Funding

07 December 2017

(8079 views)

    BlueMount Capital Secures Major Debt Funding   "In conjunction with BlueMount Capital’s Melbourne office, I am delighted to announce we have secured ...

"Walking over broken glass for sustainability"

06 December 2017

(7450 views)

    "Walking over broken glass for sustainability"   "Dr Ho’s team, along with industry partners Brisbane City Council and EnviroSand, are investigating mixtures ...

Squirrel recognised in the 2017 AFR Fast Starters List

09 November 2017

(6965 views)

  Squirrel recognised in the 2017 AFR Fast Starters List   Squirrel debut's on the Australian Financial Review's Fast Starters list, as the ...

The market, introductions and news - Funding Strategies Connect October 2017

31 October 2017

(7582 views)

    Dear Reader,   It's an interesting time in the capital markets space at the moment. Australia has seen a large initial coin offering ...

"CaroMel's platform launch set"

27 October 2017

(6962 views)

"CaroMel's platform launch set   Platform launch CaroMel’s platform is ready for launch. The company will now sprint to load the branding and ...

"We are launching any day now" CaroMel Ltd Podcast

19 October 2017

(7188 views)

    "We are launching any day now"   Podcast: Listen as Raghu Rajakumar spoke to Greg McLardie, Managing Director of CaroMel Ltd. CaroMel is ...

LeenLife signs Agreement with BioCube

17 October 2017

(7264 views)

  LeenLife Pharma International: Production and Operations in North America Exclusivity Agreement with BioCubeTM   "October 17, 2017 CSE - LLP The Company is pleased to ...

Mining, Cars and Cyber Protection - Funding Strategies Connect September 2017

06 October 2017

(6569 views)

  Dear Reader,   In discussing our services with prospects and clients, it is important to be clear on their company's strategic objectives. Quite ...

CaroMel - Director Briefing with Greg McLardie

03 October 2017

(7140 views)

  Director Briefing with Greg McLardie, CaroMel Ltd   “Our digital platform allows orders to be received from and shipped directly to the ...

Haixi - Extension of the Offer Period

28 September 2017

(7212 views)

  Haixi - Extension of the Offer Period   "The Board of Directors of Haixi Pharmaceutical International Holdings Limited (ACN 616 806 574) ...

CaroMel's platform launch set

26 September 2017

(6933 views)

CaroMel's platform launch set "CaroMel's digital platform is on track to launch within three months with the technology build, traceability and ...

"CaroMel plans 2018 IPO for global expansion of agritech marketplace - MD"

22 September 2017

(5929 views)

  "CaroMel plans 2018 IPO for global expansion of agritech marketplace - MD"   "CaroMel, an Australian digital agritech marketplace, plans to list ...

CaroMel completes minimum subscription prior to launch

19 September 2017

(6000 views)

  CaroMel completes minimum subscription prior to launch "On behalf of our team, I am delighted to announce CaroMel has completed the ...

Venture Capital updates and other news - Funding Strategies Connect August 2017

01 September 2017

(6400 views)

 Venture Capital updates and other news - Funding Strategies Connect August 2017 Dear Readers, I attended the AVCAL / Future Fund Venture ...

Project 'Glucose Biosensor'

30 August 2017

(9544 views)

  Project 'Glucose Biosensor'     Click here to watch the Project 'Glucose Biosensor' video. This is a first to market, first in class ...

CaroMel Ltd

30 August 2017

(7943 views)

   CaroMel Ltd – A digital disruption enabling fishermen and farmers to connect directly with high-end restaurants in China CaroMel Ltd aims to ...

Take a look at the new Nifty Forms site!

30 August 2017

(6120 views)

Take a look at the new Nifty Forms site!   "See how the new Nifty Forms site will make claiming R&D easier If ...

"The Tooth Booth Business Model Delivers A Much Better GP Margin Percentage"

30 August 2017

(6612 views)

  "The Tooth Booth Business Model Delivers A Much Better GP Margin Percentage   The Tooth Booth Board is pleased to announce that ...

CXi Announces Second Client for Unit Registry

29 August 2017

(6787 views)

   CXi Announces Second Client for Unit Registry   "CXi Software (“CXi”) has announced that it has successfully migrated its second client, in ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625